Options for COVID-19 Entry into Pulmonary Cells
Open Access
- 5 August 2020
- journal article
- Published by Biomedical Research Network, LLC in Biomedical Journal of Scientific & Technical Research
- Vol. 29 (2), 22337-22338
- https://doi.org/10.26717/bjstr.2020.29.004781
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2Cell, 2020
- SARS ‐CoV‐2 receptor ACE 2 and TMPRSS 2 are primarily expressed in bronchial transient secretory cellsThe EMBO Journal, 2020
- A Novel Coronavirus from Patients with Pneumonia in China, 2019The New England Journal of Medicine, 2020
- Proliferating SPP1/MERTK-expressing macrophages in idiopathic pulmonary fibrosisEuropean Respiratory Journal, 2019
- Tissue-based map of the human proteomeScience, 2015
- SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathwayCell Research, 2008
- Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entryProceedings of the National Academy of Sciences of the United States of America, 2005
- CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirusProceedings of the National Academy of Sciences of the United States of America, 2004
- Prior Infection and Passive Transfer of Neutralizing Antibody Prevent Replication of Severe Acute Respiratory Syndrome Coronavirus in the Respiratory Tract of MiceJournal of Virology, 2004
- Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirusNature, 2003